Nektar Therapeutics (NKTR) Stock

About Nektar Therapeutics

Nektar Therapeutics is led by CEO Howard W. Robin, employs 61 people, headquartered in US, publicly traded since 1994.

Nektar Therapeutics (NKTR) stock trades at $37.42 with a market capitalization of $1.07B. The stock is valued at a negative price-to-earnings (P/E) ratio of -6.50, reflecting a net loss over the last twelve months, price-to-book of 1.60, price-to-sales of 22.90. Over the past 52 weeks the stock has ranged between $33.40 and $109.00, and currently trades 65.7% below its 52-week high.

On profitability, Nektar Therapeutics generates a return on equity (ROE) of -37.99% (negative, reflecting a net loss), return on capital employed of -12.81%, an operating margin of -238.18%, a net profit margin of -287.84%.

Nektar Therapeutics by the numbers, 2016–2025

Between 2016 and 2025 Nektar Therapeutics reported revenue of $165.0M rising to $55.0M, a change of -66.7% across 10 years. Compounded, revenue has grown -18.5% a year over five years, -15.8% over three, -43.9% over the last twelve months. Net profit fell to $-164.0M.

Operating margin went from -68.2% in 2016 to -236.8% in 2025, a fall of 168.6 percentage points. The most recent net margin is -287.84%. On a trailing twelve-month basis to Jun '26, revenue is $55.0M and net profit $-158.0M.

Borrowings fell from $249.0M to $149.0M, cash from operations was $-209.0M in the latest year, positive in 1 of the last 10.

Return on equity has averaged -153.1% over five years, and was -182.2% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Nektar Therapeutics (NKTR) — frequently asked questions